When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Dinushika Mohottige, MD, a general nephrologist and assistant professor at the ICAHN School of Medicine at Mount Sinai, discusses the causes, symptoms, and treatments of kidney disease. The…
Nephrologist Sumeska Thavarajah, MD, of Johns Hopkins, discusses treatment options for end-stage kidney disease, also known as end-stage renal disease. The treatments include dialysis, transplantation, or medical management,…
